406 related articles for article (PubMed ID: 18390417)
1. [Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
[TBL] [Abstract][Full Text] [Related]
2. [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Lind JS; Herder GJ; Smit EF
Ned Tijdschr Geneeskd; 2008 Apr; 152(16):928-32. PubMed ID: 18561788
[TBL] [Abstract][Full Text] [Related]
3. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
5. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
7. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C
Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
9. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Mendoza L
Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Pakkala S; Ramalingam SS
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Grenier J; Soria JC
Bull Cancer; 2007 Jan; 94(1):53-61. PubMed ID: 17237005
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
17. New insights in drug development for the non-small cell lung cancer therapy.
Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
[TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
[TBL] [Abstract][Full Text] [Related]
19. [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Italiano A; Besse B; Planchard D; Soria JC
Bull Cancer; 2007; 94(7 Suppl):F177-88. PubMed ID: 17964994
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
